Ovarian cancer (OC) remains a fatal malignancy because most patients experience recurrent disease, which is resistant to chemotherapy. The outcomes for patients with platinum-resistant OC are poor, response rates to further chemotherapy are low and median survival is lower than 12 months. The complexity of platinum-resistant OC, which comprises a heterogeneous spectrum of diseases, is indeed far from being completely understood. Therefore, comprehending tumors’ biological behaviour to identify reliable biomarkers, which may predict responses to therapies, is a demanding challenge to improve OC management. In the age of precision medicine, efforts to overcome platinum resistance in OC represent a dynamic and vast field in which innovative drugs and clinical trials rapidly develop. This review will present the exceptional biochemical environment implicated in OC and highlights mechanisms of chemoresistance. Furthermore, innovative molecules and new therapeutic opportunities are presented, along with currently available therapies and ongoing clinical trials.

卵巢癌 (OC) 仍然是一种致命的恶性肿瘤，因为大多数患者会出现复发性疾病，这种疾病对化疗有抵抗力。铂类耐药 OC 患者的预后较差，对进一步化疗的反应率较低，中位生存期低于 1​​2 个月。铂耐药性 OC 的复杂性包括多种疾病，确实远未完全了解。因此，了解肿瘤的生物学行为以识别可靠的生物标志物，从而预测对治疗的反应，是改善 OC 管理的一项艰巨挑战。在精准医疗时代，克服OC中铂类耐药的努力代表了一个充满活力和广阔的领域，创新药物和临床试验在其中迅速发展。这篇综述将介绍与 OC 有关的特殊生化环境，并强调化学抗性的机制。此外，还介绍了创新分子和新的治疗机会，以及目前可用的疗法和正在进行的临床试验。